Using ELISAs, we determined the concentrations of transforming growth factor a (TGF-ct),the extracellular domain of the erbB-2 receptor (erbB-2 ECD), and mutant p53 protein in stored serum samples of asbestosis patients with and without cancer and control subjects (without asbestosis or cancer). The percentage of individuals in these three groups with increased serum concentrations of TGF-a, erbB-2 ECD, and mutant p53, respectively, were: asbestosis patients with cancer, 36%, 16%, 19%; asbestosis patients without cancer, 38%, 19%, 6%; control subjects, 0%, 5%, 10%. Although differences in serum positivity for these oncoproteins were apparent among these groups, the differences did not achieve statistical significance (P >0.05). In several of the cancer cases, increased concentrations of TGF-a, erbB-2 ECD, and mutant p53 were also detected in the stored serum samples collected years before the clinical diagnosis of disease.
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Recent progress in understanding the molecular biology of cancer has provided a range of potential new biomarkers with which to study the effects of exposure to environmental carcinogens. For example, in many cases, the effects ofenvironmental carcinogensare likelyto be mediated by alterations in growth factorsor the protein products of oncogenes and tumor suppressor genes (1, 2). These alterationslead to increased expression of the encoded proteins or expression of mutant forms of the encoded proteins in affected cells (1, 2) . Furthermore, in some instances, these proteins appear to gain access to the extracellular environment; thus, these changes can be detected in vivo by assaying for these proteins in easily accessible biological fluids such as serum (1, 2) .
Three such potential biomarkers are transforming growth factor a (TGF-a), the extracellular domain of the transmembrane growth factor receptor encoded by the c-erbB-2 oncogene (erbB-2 ECD), and the mutant forms of the protein of the p.5,3 tumor suppressor gene (mutant p53).6 All of these proteins are involved in the regulation We have examined TGF-a, erbB-2 ECD, and mutant p53 in stored serum samples from individuals with asbestosis with and without cancer and in normal control subjects.
In this report, we present the results for the serum erbB-2 ECD in these individuals that were reported previously (3, 4) and the preliminary results to date for some of the individuals in these groups for serum TGF-a and serum mutant p53, which have not been reported previously.
Materialsand Methods
A . All serum samples for the 111 Finnish asbestosis patients and the 20 American control subjects were assayed for the erbB-2 ECD. For TGF-a, the serum samples from 107 of the asbestosis patients and 10 of the control subjects have been assayed thus far;for mutant p53, 68 and 10 samples, respectively,have been assayed thus far. For TGF-a and erbB-2 ECD, a positive increase in the serum concentration was defined as any value that exceeds the mean + 2 SD of the control group, because the concentrations of these proteins tend to follow a normal distribution. For mutant p53, a positive increase in the serum concentration has been arbitrarily defined as any value that is greater than four times the lower limit of detection of the assay, i.e., >0.20 pgfL. All procedures followed were in accordance with the ethical standards of the respective participating institutions.
Results
The percentages of individuals with positive serum samples for TGF-a and erbB-2 ECD were approximately the same for asbestosis patients with or without cancer, and both were somewhat higher than the percentages among the nonasbestosis control subjects (Tables 1 and 2 ). The percentages of individuals with positive serum samples for mutant p53 were approximately the same for the asbestosis patients without cancer and the nonasbestosis controls, and both were lower than the percentage among the asbestosis pa- 
Serum mutant p53
a Since most of the samples were nondetectableformutant p53, these figuresrepresent the mean ±SD for the positive samples only.
b Positivity defined as value greater than four times the lower limit of detection of theassay,i.e., >0.20 jg/L. tients with cancer (Table 3) . However, the differences in the percentages of positive individuals among the cancer cases compared with the asbestosis controls or the nonasbestosis controls did not achieve statistical significance for any of the three assays (TGF-a, erbB-2 ECD, or mutant p53) (Fisher's exact, P >0.05). All patients positive for cancer who had multiple stored serum samples available for analysis had at least one positive sample before disease was diagnosed. in this study, the individual with adenocarcinoma of the lung who was serum-positive for TGF-ct and mutant p53 was also serum-positive for rag p21; the individual with pancreatic carcinoma who was serum-positive for TGF-a was also serum-positive for 
